MedPath

Geriatric Psychiatry and Pharmacovigilance

Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Registration Number
NCT01858857
Lead Sponsor
Hannover Medical School
Brief Summary

The purpose of this observational multicenter-study is to investigate safety of psychopharmacological treatment and rates of adverse drug reactions in gerontopsychiatric inpatients. Elderly people are at higher risk for developing side effects under pharmacological treatment due to an altered metabolic situation, higher comorbidity rates and often polypharmacy. Furthermore gerontopsychiatric patients can often not articulate their symptoms clearly, for example due to pronounced cognitive impairment.

The aim of the study is to gain valid data of possible adverse drug reaction rates, their potential risk factors and outcome, as well as medical prescription practises.

To assess these outcomes an intensive pharmacovigilance-monitoring will be conducted at the five participating study sites.

At Baseline demographic data, previous and present disorders, use of drugs, previous and present medication, quality of life, cognitive function, physical examination results, laboratory results and ECG will be assessed.

Afterwards patients are visited weekly and screened for possible adverse drug reactions. All adverse drug reactions will be coded in the MedDRA-system.

In case of a possible serious adverse drug reaction serum levels of all psychotropic substances applicated will be assessed. Drug combinations will be analysed using an established advanced bioinformatic tool (mediQ). Diagnosis, medication intake and possible adverse drug reactions are documented continually.

2 weeks after discharge from the ward, patients will be contacted by phone to assess catamnestic data.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
4000
Inclusion Criteria
  1. Age 65+ years old
  2. Inpatients treated at one of the geriatric psychiatry study sites.
  3. Signed consent form ( Patient and/or legally authorized custodian)
Exclusion Criteria
  1. Patients that are incapable to give their informed consent and are not under legally authorized custodianship.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Assessment of frequency and severity of adverse events in geriatric psychiatry inpatients under psychopharmacological treatmentPatients will be monitored continuosly during the hospital stay (expected average of 4 weeks) and at follow-up, which is 2 weeks after discharge.
Secondary Outcome Measures
NameTimeMethod
Assessment of cognitive functioningAt baseline visit and last visit, max. 3 days before discharge from the ward (expected average of hospital stay: 4 weeks).

Mini Mental State Exam

Quality of lifeAt baseline visit and last visit, max. 3 days before discharge from the ward (expected average of hospital stay: 4 weeks).
Adverse drug reactionsPatients will be monitored continuosly during the hospital stay (expected average of 4 weeks) and at follow-up, which is 2 weeks after discharge.
Serum levels of substances1 day at occurence of SAE
ElectrocardiogramAt baseline visit and last visit, max. 3 days before discharge from the ward (expected average of hospital stay: 4 weeks).
Medication intakePatients medication intake 2 weeks before hospitalisation, continuosly during the hospital stay and at follow-up 2 weeks after discharge will be assessed (expected average of 8 weeks).

Before hospitalisation and after discharge by interview, during the hospital stay by patients chart.

Trial Locations

Locations (5)

Krankenhaus Hedwigshöhe

🇩🇪

Berlin, Germany

Hannover Medical School

🇩🇪

Hannover, Germany

Asklepios Fachklinikum Teupitz

🇩🇪

Teupitz, Germany

Asklepios Fachklinikum Brandenburg

🇩🇪

Brandenburg an der Havel, Germany

Asklepios Fachklinikum Lübben

🇩🇪

Lübben, Germany

© Copyright 2025. All Rights Reserved by MedPath